Annexon, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Annexon, Inc. on October 4, 2021, covering events that occurred on September 30, 2021. The Company is a Delaware corporation with its principal executive offices in South San Francisco, California. Its common stock trades on The Nasdaq Stock Market under the symbol "ANNX". The Company is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance and personnel changes.
Material Changes
The primary material change reported is the restructuring of senior executive leadership effective September 30, 2021:
- Ted Yednock, Ph.D. was appointed as Chief Innovation Officer. He previously served as Chief Scientific Officer from 2013 until this date.
- Larry Mattheakis, Ph.D. was appointed as Chief Scientific Officer.
Guidance, Outlook, and Risks
The filing includes a press release (Exhibit 99.1) announcing the leadership appointments, stating the Company is strengthening its executive leadership team. No financial guidance, outlook, specific risk factors, or contingencies are disclosed in this document. The information provided in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the specific roles and responsibilities assigned to Dr. Yednock and Dr. Mattheakis in the accompanying press release.
- Confirm the effective date of the leadership transition (September 30, 2021).
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.